Drug Repurposing Patent Applications October–December 2020

Burnat P , Payen A , Le Brumant-Payen C , Hugon M , Ceppa F : Bromontan, a new doping agent. Lancet, 1997; 350:963–964.

Oliynyk S , Oh S : The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul), 2012; 20:446–456.

Sergeeva SA , Krapivin SV , Losev AS , Morozov IS : [Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane]. Biull Eksp Biol Med, 1995; 119:305–308.

Morozov IS , Klimova NV , Sergeeva SA , et al.: [Adamantane derivatives enhancing body's resistance to emergencies]. Vestn Ross Akad Med Nauk, 1999; 3:28–32.

Ju C , Colgan SP , Eltzschig HK : Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl), 2016; 94:613–627.

Shu S , Wang Y , Zheng M , et al.: Hypoxia and hypoxia-inducible factors in kidney injury and repair. Cells, 2019; 8:207.

Voelkel NF , Mizuno S , Bogaard HJ : The role of hypoxia in pulmonary vascular diseases: a perspective. Am J Physiol Lung Cell Mol Physiol, 2013; 304:L457–L465.

Zhang D , Chen G , Manwani D , et al.: Neutrophil ageing is regulated by the microbiome. Nature, 2015; 525:528–532.

Lim SH , Morris A , Li K , et al.: Intestinal microbiome analysis revealed dysbiosis in sickle cell disease. Am J Hematol, 2018; 93:E91–E93.

Dutta D , Methe B , Amar S , Morris A , Lim SH : Intestinal injury and gut permeability in sickle cell disease. J Transl Med, 2019; 17:183.

Lim SH , Dutta D , Moore J : Rifaximin for sickle cell disease. Am J Hematol, 2019; 94:E325–E328.

Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2017; 16:505–512.

Watanabe T , Tanaka M , Watanabe K , Takamatsu Y , Tobe A : [Research and development of the free radical scavenger edaravone as a neuroprotectant]. Yakugaku Zasshi, 2004; 124:99–111.

Kikuchi K , Uchikado H , Miyagi N , et al.: Beyond neurological disease: new targets for edaravone (Review). Int J Mol Med, 2011; 28:899–906.

Nakamaru Y , Kakubari M , Yoshida K , et al.: Open-label, single-dose studies of the pharmacokinetics of edaravone in subjects with mild, moderate, or severe hepatic impairment compared to subjects with normal hepatic functioning. Clin Ther, 2020; 42:1467–1482.e4.

Sumida Y , Niki E , Naito Y , Yoshikawa T : Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res, 2013; 47:869–880.

Thakker PD , Braverman AC : Cardiogenetics: genetic testing in the diagnosis and management of patients with aortic disease. Heart 2020 [Epub ahead of print]; DOI: 10.1136/heartjnl-2020-317036.

Pang P , Hu X , Zhou B , et al.: DDX24 mutations associated with malformations of major vessels to the viscera. Hepatology, 2019; 69:803–816.

Araújo AC , Tang X , Haeggström JZ : Targeting cysteinyl-leukotrienes in abdominal aortic aneurysm. Prostaglandins Other Lipid Mediat, 2018; 139:24–28.

Nicholson SL , Brotchie JM : 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease—opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol, 2002; 9 Suppl 3:1–6.

Kannari K , Kurahashi K , Tomiyama M , et al.: Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei, 2002; 54:133–137.

Bernstein JA : Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin, 2007; 23:2441–2452.

McTavish D , Sorkin EM : Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs, 1989; 38:778–800.

Hatakeyama A , Fujii M , Hatakeyama R , Fukuoka Y , Satoh-Nakagawa T , Sasaki H : Azelastine hydrochloride on behavioral and psychological symptoms and activities of daily living in dementia patients. Geriatr Gerontol Int, 2008; 8:59–61.

Rafferty P , Harrison PJ , Aurich R , Holgate ST : The in vivo potency and selectivity of azelastine as an H1 histamine-receptor antagonist in human airways and skin. J Allergy Clin Immunol, 1988; 82:1113–1118.

Muñoz M , Coveñas R : The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?. Cancers (Basel), 2020; 12:2682.

Munoz M , Covenas R , Esteban F , Redondo MJ : The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci, 2015; 40:441–463.

Robinson P , Martin P Jr. , Garza A , D'Souza M , Mastrangelo MA , Tweardy D : Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice. J Parasitol, 2008; 94:1150–1154.

Rodgers J , Bradley B , Kennedy PG : Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Parasitol Int, 2007; 56:321–324.

Brito-Zerón P , Baldini C , Bootsma H , et al.: Sjogren syndrome. Nat Rev Dis Primers, 2016; 2:16047.

Gopalakrishnan S , Durai M , Kitchens K , et al.: Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides, 2012; 35:86–94.

Khaleghi S , Ju JM , Lamba A , Murray JA : The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol, 2016; 9:37–49.

Troisi J , Venutolo G , Terracciano C , et al.: The therapeutic use of the zonulin inhibitor AT-1001 (Larazotide) for a variety of acute and chronic inflammatory diseases. Curr Med Chem 2021 [Epub ahead of print]; DOI: 10.2174/0929867328666210104110053.

de Boer T : The pharmacologic profile of mirtazapine. J Clin Psychiatry, 1996; 57 Suppl 4:19–25.

Haddjeri N , Blier P , de Montigny C : Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol, 1995; 10 Suppl 4:11–17.

Bendtsen L , Evers S , Linde M , Mitsikostas DD , Sandrini G , Schoenen J : EFNS guideline on the treatment of tension-type headache—report of an EFNS task force. Eur J Neurol, 2010; 17:1318–1325.

Wakerley BR : Medication-overuse headache. Pract Neurol, 2019; 19:399–403.

Singh RN , Singh NN : Mechanism of splicing regulation of spinal muscular atrophy genes. Adv Neurobiol, 2018; 20:31–61.

Singh NN , Singh RN : How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene. Biochim Biophys Acta Gene Regul Mech, 2019; 1862:194403.

Konieczny P , Artero R : Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA. FASEB J, 2020; 34:3021–3036.

Menduti G , Rasà DM , Stanga S , Boido M : Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment. Front Pharmacol, 2020; 11:592234.

Van Dijck A , Vulto-van Silfhout AT , Cappuyns E , et al.: Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP. Biol Psychiatry, 2019; 85:287–297.

Bend EG , Aref-Eshghi E , Everman DB , et al.: Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome. Clin Epigenetics, 2019; 11:64.

Malishkevich A , Leyk J , Goldbaum O , Richter-Landsberg C , Gozes I : ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. J Mol Neurosci, 2015; 57:304–313.

Turner CP , Gutierrez S , Liu C , et al.: Strategies to defeat ketamine-induced neonatal brain injury. Neuroscience, 2012; 210:384–392.

Brown BP , Kang SC , Gawelek K , et al.: In vivo and in vitro ketamine exposure exhibits a dose-dependent induction of activity-dependent neuroprotective protein in rat neurons. Neuroscience, 2015; 290:31–40.

Strupp M , Mandalà M , López-Escámez JA : Peripheral vestibular disorders: an update. Curr Opin Neurol, 2019; 32:165–173.

Hegemann SCA , Wenzel A : Diagnosis and treatment of vestibular neuritis/neuronitis or peripheral vestibulopathy (PVP)? Open questions and possible answers. Otol Neurotol, 2017; 38:626–631.

Tighilet B , Chabbert C : Adult neurogenesis promotes balance recovery after vestibular loss. Prog Neurobiol, 2019; 174:28–35.

Chiarella G , Russo D , Monzani F , et al.: Hashimoto thyroiditis and vestibular dysfunction. Endocr Pract, 2017; 23:863–868.

Möller M , Wasel J , Schmetzer J , et al.: The specific IKKepsilon/TBK1 inhibitor amlexanox suppresses human melanoma by the inhibition of autophagy, NF-kappaB and MAP kinase pathways. Int J Mol Sci, 2020; 21:4721.

Wang N , Li Y , Wang X , et al.: Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury. Toxicology, 2020; 443:152555.

Qi J , Zhou Z , Lim CW , Kim JW , Kim B : Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice. Toxicol Appl Pharmacol, 2019; 385:114767.

Mo C , Ha H , Tang X , et al.: Protein kinase TBK1/IKKepsilon inhibitor Amlexanox improves cardiac function after acute myocardial infarction in rats. Panminerva Med, 2020 [Epub ahead of print]; DOI: 10.2373/6/S0031-0808.20.03937-3.

Quan MY , Song XJ , Liu HJ , et al.: Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses. J Neuroinflammation, 2019; 16:52.

Yu S , Chen J , Wu M , Chen H , Kato N , Yuan Z : Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol, 2010; 91(Pt 8):2080–2090.